Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-732-7 | CAS number: 13952-84-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Isopropylamine
- EC Number:
- 200-860-9
- EC Name:
- Isopropylamine
- Cas Number:
- 75-31-0
- Molecular formula:
- C3H9N
- IUPAC Name:
- propan-2-amine
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
Administration / exposure
- Route of administration:
- inhalation: vapour
- Vehicle:
- air
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 6 h/d, 5d/wk
Doses / concentrationsopen allclose all
- Dose / conc.:
- 20 mg/m³ air (analytical)
- Remarks:
- Doses / Concentrations:
20, 101, and 499 mg/m3
Basis:
analytical conc.
- Dose / conc.:
- 101 mg/m³ air (analytical)
- Dose / conc.:
- 499 mg/m³ air (analytical)
- No. of animals per sex per dose:
- 15
- Control animals:
- yes, concurrent no treatment
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A low level female and a high level male died approxtiately
12 weeks into the study. The reason for the death of the low <-
level female could not be determined, but it was not thought to’
be treatment-related. The death of the high level animal was due
to mechanical trauma and was not treatment-related. There were
no clinical observations which were clearly related to test
material exposure (Table 1). - Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean body weight of high exposure level males was reduced throughout
much of the study. The mean body weight of high exposure level males was reduced (approximately 6-9%) throughout most of the study (Table 4).
Slight (approximately 4-6%) body weight reductions were also noted in high level females during weeks 6-13. The mean body
weights of low and mid exposure level antials were unchanged. - Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthahic examinations revealed no
treatment-related eye lesions. - Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The WBC count was significantly decreased in high exposure level
males (Table 10). Erythrocyte parameters (RBC, HCT, HGB) were
increased in all male exposure groups. The reticulocyte count
was decreased in high level males. The MCHC values were
decreased in all three female’exposure groups. However, the
changes were minimal (<3.5%), not dose-related, and thus not
considered to be treatment-related. - Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Serum glucose was decreased. Sodium was decreased in mid and high level
females, but the changes were minimal (<1.4%) and not consideredto be biologically significant. Increased serum potassium values in mid and high level males were not dose-related and thus not considered to be treatment-related. - Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The increased absolute and relative adrenal weights in high level
females were probably treatment-related and may have been a
non-specific response to stress. The reduced spleen weights in
high level males were due, at least in part, to the decreased
body weights in these animals - Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
The absolute and relative adrenal weights were significantly increased (approximately 18 and 22%, respectively) in high level females (Tables 17 and 18). Absolute spleen weights were significantly decreased (approximately 15%) in high level males.
There was no gross pathology change which was considered to be treatment-related (Table 12). The only microscopic change which occurred at a statistically significant incidence was inflammation of the nasal mucosa in high level females
(Table 15).
There were slight increases in centrilobular hepatocellular hypertrophy and individual hepatocellular necrosis in livers of high dose males relative to controls. The severity levels for both lesions were minimal in all but one instance in which ~~
hepatocellular necrosis occurred at moderate severity. These < changes were not considered to have been related to treatment since there were no comparable increases in females and since “’. these changes at minimal levels of severity are often observed in untreated rats of this strain,and age.
Likewise, mononuclear cell infiltrate occurred in kidneys of high dose females at a slightly higher incidence than for controls.
This is an extremely common lesion in untreated animals of this strain and age and therefore, the” small numbers obsemed were
considered to be spontaneous and unrelated to chemical exposure.
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 500 mg/m³ air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: systemic effects (excluding local effects)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 100 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: local effects: histopathology (nose)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The NOAEC was 100 mg/m3for local effects and 500 mg/m³ for systemic effects.
- Executive summary:
In a study conducted in a manner equivalent or similar to OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day), groups of 15 male and female Sprague-Dawley rats were exposed by vapor inhalation for 6 h/d, 5d/w for 13 weeks to 20, 101, and 499 mg/m3isopropylamine(Heydens and Thake, 1988). The highest concentration, 500 mg/m3(LOAEC), produced nasal inflammation (females), a slight decrease in body weight of < 7 % (males), and a slight decrease in serum-glucose level (females). The systemic effects were considered to be of no pathological relevance.
The NOAEC was 100 mg/m3for local effects and 500 mg/m³ for systemic effects.
Because of the highly irritating activity of isopropylamine, oral and dermal application was not indicated.
The following information is taken into account for any hazard / risk assessment:
Isopropylamine produced no systemic but local effects (nasal inflammation in rats exposed to 500 mg/m3 for 13 weeks), while 100 mg/m3 showed no adverse effects at all.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.